22 October 2018 - - US-based Exelixis, Inc. (NASDAQ: EXEL) has published results from two analyses evaluating the effect of PD-L1 expression or prior treatment with immune checkpoint inhibitors on the efficacy of cabozantinib in patients with ad...
22 October 2018 - - US-based ImmunoGen, Inc., (NASDAQ: IMGN), a specialist in the field of antibody-drug conjugates for the treatment of cancer, has announced initial safety and preliminary anti-tumor activity from the FORWARD II expansion cohort ass...
22 October 2018 - - US-based biopharmaceutical company Pfizer Inc. (NYSE: PFE) has released detailed overall survival data from the PALOMA-3 trial, which evaluated Ibrance (palbociclib) in combination with fulvestrant compared to placebo plus fulvest...
22 October 2018 - - US-based biopharmaceutical company Bristol-Myers Squibb Company (NYSE: BMY) has published follow-up data evaluating Opdivo (nivolumab) monotherapy and Opdivo in combination with Yervoy (ipilimumab) in...
22 October 2018 - - US-based biopharmaceutical company Merck (NYSE: MRK) has presented results from an interim analysis of KEYNOTE-057, a Phase 2 trial evaluating Keytruda, Merck's anti-PD-1 therapy, for previously treated patients with high-ris...